AVNS Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies has a net margin of 3.94% compared to Avanos Medical's net margin of -163.76%. Avanos Medical's return on equity of -35.96% beat NeuroOne Medical Technologies's return on equity of -281.01%.

Avanos Medical has a consensus price target of $14.00, signalling upside risk potential of 14.66%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of $1.45 which suggests that it could grow by 113.24%. Given that NeuroOne Medical Technologies has higher upside potential than Avanos Medical, analysts believe NeuroOne Medical Technologies is more attractive than Avanos Medical.

Avanos Medical has a beta of 1.141, which suggesting that the stock is 14.144% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.725, suggesting its less volatile than the S&P 500 by 27.531%.

Avanos Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avanos Medical pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.

Avanos Medical quarterly revenues are $167.5M, which are larger than NeuroOne Medical Technologies quarterly revenues of $1.4M. Avanos Medical's net income of $6.6M is higher than NeuroOne Medical Technologies's net income of -$2.3M. Notably, Avanos Medical's price-to-earnings ratio is 45.94x while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avanos Medical is 0.82x versus 3.52x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of 3.94% compared to Avanos Medical's net margin of -208.09%. Avanos Medical's return on equity of -35.96% beat Nutriband's return on equity of -102.63%.

Avanos Medical has a consensus price target of $14.00, signalling upside risk potential of 14.66%. On the other hand Nutriband has an analysts' consensus of $15.00 which suggests that it could grow by 87.97%. Given that Nutriband has higher upside potential than Avanos Medical, analysts believe Nutriband is more attractive than Avanos Medical.

Avanos Medical has a beta of 1.141, which suggesting that the stock is 14.144% more volatile than S&P 500. In comparison Nutriband has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.694%.

Avanos Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avanos Medical pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

Avanos Medical quarterly revenues are $167.5M, which are larger than Nutriband quarterly revenues of $667.4K. Avanos Medical's net income of $6.6M is higher than Nutriband's net income of -$1.4M. Notably, Avanos Medical's price-to-earnings ratio is 45.94x while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avanos Medical is 0.82x versus 36.93x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

enVVeno Medical has a net margin of 3.94% compared to Avanos Medical's net margin of --. Avanos Medical's return on equity of -35.96% beat enVVeno Medical's return on equity of --.

Avanos Medical has a consensus price target of $14.00, signalling upside risk potential of 14.66%. On the other hand enVVeno Medical has an analysts' consensus of $12.50 which suggests that it could grow by 207.13%. Given that enVVeno Medical has higher upside potential than Avanos Medical, analysts believe enVVeno Medical is more attractive than Avanos Medical.

Avanos Medical has a beta of 1.141, which suggesting that the stock is 14.144% more volatile than S&P 500. In comparison enVVeno Medical has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.843%.

Avanos Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. enVVeno Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avanos Medical pays -- of its earnings as a dividend. enVVeno Medical pays out -- of its earnings as a dividend.

Avanos Medical quarterly revenues are $167.5M, which are larger than enVVeno Medical quarterly revenues of --. Avanos Medical's net income of $6.6M is higher than enVVeno Medical's net income of -$4.5M. Notably, Avanos Medical's price-to-earnings ratio is 45.94x while enVVeno Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avanos Medical is 0.82x versus 397.04x for enVVeno Medical. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of 3.94% compared to Avanos Medical's net margin of -787.63%. Avanos Medical's return on equity of -35.96% beat SINTX Technologies's return on equity of -180.99%.

Avanos Medical has a consensus price target of $14.00, signalling upside risk potential of 14.66%. On the other hand SINTX Technologies has an analysts' consensus of $28.00 which suggests that it could grow by 769.57%. Given that SINTX Technologies has higher upside potential than Avanos Medical, analysts believe SINTX Technologies is more attractive than Avanos Medical.

Avanos Medical has a beta of 1.141, which suggesting that the stock is 14.144% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.368%.

Avanos Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avanos Medical pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

Avanos Medical quarterly revenues are $167.5M, which are larger than SINTX Technologies quarterly revenues of $291K. Avanos Medical's net income of $6.6M is higher than SINTX Technologies's net income of -$2.3M. Notably, Avanos Medical's price-to-earnings ratio is 45.94x while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avanos Medical is 0.82x versus 3.09x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.